Latest news with #Garg
Time of India
6 hours ago
- Time of India
DRM Nagpur, inspects Godhani station with eye on boosting efficiency
Nagpur: Vinayak Garg, divisional railway manager (DRM), Central Railway, Nagpur, conducted an inspection of Godhani station as part of the Amrit Bharat Station Scheme. This scheme aims at modernising railway infrastructure and enhancing operational efficiency. The inspection focused on optimising train movements along the critical Delhi-Howrah and Howrah-Delhi corridors, which handle eight pairs of long-distance trains daily. Garg reviewed the Godhani–Kalamna rail link and proposed diverting select long-distance trains via Kalamna Station, under South East Central Railway's jurisdiction. This move aims to bypass Nagpur station, eliminating engine reversals, reducing congestion, and saving operational time. The diversion is expected to improve train punctuality, streamline traffic management, and enhance route efficiency. The initiative aligns with Central Railway's commitment to inter-zonal coordination and capacity optimisation, ensuring smooth operations on one of Indian Railways ' busiest routes. The Amrit Bharat Station Scheme emphasises developing future-ready stations with advanced infrastructure and passenger amenities. This inspection underscores Central Railway's dedication to long-term planning and infrastructure upgrades, paving the way for a more efficient and passenger-friendly railway network.
Hindustan Times
a day ago
- Business
- Hindustan Times
India ‘disappointed' after talks at Bonn
India and several developing countries have expressed disappointment after a key climate finance discussion was excluded from the Bonn Climate Talks agenda, vowing to raise the issue at November's COP30 summit in Brazil. The dispute centred on Article 9.1 of the Paris Agreement, which mandates that developed countries provide financial resources to assist developing nations with both mitigation and adaptation efforts. The debate over the 9.1 agenda item proposal led to a 30-hour delay before talks could begin. 'We are extremely disappointed with the reluctance of developed countries to discuss their legal obligations to provide finance to developing countries,' said Amandeep Garg, additional secretary at ministry of environment, forests and climate change, who represented the Indian delegation. The Like Minded Developing Countries (LMDC) group and the G77 and China had proposed agenda items on both the legal obligation of wealthy countries to provide climate finance and another on unilateral trade measures. However, these were not adopted after the European Union and other developed nations refused to agree. 'Without enough affordable financial support, developing countries cannot address the challenges posed by climate change,' Garg said during his intervention at the agenda adoption session, backing the LMDC position. 'This is completely unacceptable. We do not understand how this process can engage in article 9.1 without which climate action in developing countries cannot be taken in scale, scope and speed' Garg added: 'It has been 10 years of the Paris Agreement and still the items which are required to be discussed, we are not discussing them.' Diego Pacheco, Bolivia's negotiator and spokesperson for the LMDC group, warned that the issue would resurface at COP30. 'Public finance from developed countries is a necessary condition for implementation of the Paris Agreement,' he said. 'You can deny us the starting point but be rest assured, the LMDC will raise these items at COP30.' The African Group also highlighted the implementation of Article 9.1 as critical to their region, emphasising the need to address resource provision for nationally determined contributions, national adaptation plans, and just transition measures. EU negotiators said their 'positions and motivations being mischaracterised' and urged parties to respect all positions in a constructive spirit. The agenda was finally adopted on Tuesday evening after extensive behind-closed-doors consultations. Simon Stiell, the UN climate chief, acknowledged the difficulty of the negotiations whilst urging progress on mandated items. 'The past 30 hours have been hard and have not reflected the urgency that we face,' Stiell said. 'Through cooperation and compromise, we have resolved the impasse. We must now move the work ahead.' This year's Bonn talks agenda includes discussions on Global Goal on Adaptation indicators under the UAE–Belém Work Programme, the UAE Dialogue on implementing global stocktake outcomes, the UAE Just Transition Work Programme, and the Baku to Belem roadmap to 1.3 trillion dollars. Avantika Goswami, programme manager at the Climate Change Centre for Science and Environment, said the European Union and its allies had blocked the G77's demand to discuss developed countries' climate finance obligations. 'The fight is not over, as the LMDC bloc and India have vowed to bring focus back to this at COP30,' she said. The dispute comes as climate change appears to be losing prominence in some international forums. The International Institute of Sustainable Development noted that G7 statements following recent talks between leaders in Kananaskis omitted references to climate change, with only the chair's summary making a passing reference to the issue. 'The G7 sidestepped climate change in the leaders' statements, despite acknowledging increased wildfires,' said Patricia Fuller, IISD president and chief executive. 'Previous G7 commitments to action on climate change remain on the books and must be delivered.'
Business Wire
a day ago
- Business
- Business Wire
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA ® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to both scientific opportunity and patient need. 'I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,' said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. 'In recent years, we've made remarkable progress across all facets of our innovation engine, achieving numerous drug approvals and positive Phase 3 readouts, and rapidly increasing the size of our clinical pipeline. As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases.' 'As we begin this exciting new chapter, I am energized about what lies ahead for Alnylam R&D and for patients,' said Dr. Garg. 'I believe we are just beginning to scratch the surface of what RNAi therapeutics can do to improve human health. Our ambition is to deliver RNAi therapeutics to every major tissue in the body and thereby address many additional diseases that lack effective treatments. It's a privilege for me to have the opportunity to work with and lead an integrated R&D organization that has already validated a new class of medicines so that we can imagine the next generation of treatments, drive them from the lab to approval, and help patients live healthier lives.' Dr. Garg joined Alnylam in 2014 to build and lead the Company's Development group. He previously held leadership roles at Bristol-Myers Squibb and Millennium Pharmaceuticals. He received a B.A. with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco (UCSF). He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining the industry. About RNAi Therapeutics RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectation that a combined R&D organization will accelerate pipeline progress; Alnylam's ability to scale its impact and transform the lives of patients across a growing number of diseases; the potential for RNAi therapeutics to improve human health; Alnylam's ability to deliver RNAi therapeutics to every major tissue in the body and to address many additional diseases that lack effective treatments; and Alnylam's ability to imagine the next generation of treatments, achieve regulatory approval for additional treatments and to help patients live healthier lives should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its 'Alnylam P 5 x25' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Hindustan Times
3 days ago
- Hindustan Times
Leopard spotted in north Delhi next to Yamuna Biodiversity Park
A leopard was spotted in the dense urban landscape of Jagatpur village in north Delhi, in a field adjacent to the Yamuna Biodiversity Park, on Sunday night. The sighting was caught on a camera trap set up by a wildlife enthusiast after locals reported several sightings of a leopard-like creature over the past few months. Delhi's forest and wildlife department said it has now deployed a team in the area to scan for pugmarks and possible signs of the animal. Hemant Garg, 41, who set up the camera trap, said he was in the village last month for birding when locals told him of a possible leopard in the area. 'They were convinced a leopard was here and showed me pugmarks. I was convinced and set up a camera trap on Sunday. On the same night, the leopard was recorded at 10.27pm,' said Garg, who recently recorded the first sighting of the Indian grey wolf in Delhi since the 1940s, in Palla not far from Jagatpur. Leopards are not rare in Delhi or this part of the city. Last year, a five year-old male leopard wandered into Jagatpur village and attacked eight people before stick-wielding villagers beat it and trapped it in a house, from where it was successfully rescued after nearly five hours by the state forest and wildlife department. In 2016, a leopard was sighted several times at the Yamuna Biodiversity Park before it was captured in a cage and translocated. The forest department said a team was deployed to Jagatpur and the surrounding area on Monday to locate the animal. 'While no one from the village contacted us, we got to know that a leopard has been caught on camera. Accordingly, a team has been deployed in the area for surveillance,' said a senior forest department official, adding that sensitisation workshops with villagers in Jagatpur and other parts of leopard-prone areas in Delhi have been ongoing since last year. Mehfooz Ali, 65, a Jagatpur local, said the camera trap was set up 50 metres from his farm. 'I have seen the animal at least four times. I first saw what looked like a leopard in January and since then others have also seen it. We were convinced it was a leopard but we did not have proof,' he said, adding that they want better security in the area. The Asola Bhatti Wildlife Sanctuary in south Delhi, which counted eight leopards in its last census in 2022, is now believed to have at least 12, according to wildlife officials. In December 2023, a leopard was spotted over multiple days in Sainik Farms, too. 'Since last year, we have been focusing on workshops for sensitisation and on man-animal conflicts,' the forest official added. Faiyaz Khudsar, scientist in-charge of the Delhi Development Authority's Biodiversity Parks programme, said the Yamuna floodplains are known to have both prey and predators. 'Historically, we have seen leopards in both the Aravalli ranges and across the Yamuna floodplains landscape. The Yamuna offers a corridor for the animal to move,' he said.
Time of India
3 days ago
- Business
- Time of India
Indian consumers shift toward homegrown kitchenware as lifestyle changes drive demand
The Indian kitchenware and lifestyle market is undergoing a significant transformation, fueled by evolving consumer habits, rising health awareness, and the growing popularity of smart, space-saving home solutions. As urban households become smaller and lifestyles busier, there is a surge in demand for durable, food-safe, and stylish kitchen products made in India. According to industry estimates, the Indian kitchenware and home storage market is expected to grow at a CAGR of over 15% by 2030. 'Consumers are now more conscious about what they bring into their kitchens—BPA-free materials, food-grade plastics, and products that balance convenience with safety are top priorities,' says Archit Garg, Director of Air Lock, a kitchenware brand leveraging a direct-selling MLM model. While international brands still hold market share, Indian manufacturers are quickly gaining ground. Local companies are not only offering quality kitchenware that meets global standards, but are also adopting models like multi-level marketing (MLM) to build community-based sales networks—especially empowering women and homemakers. 'Our aim is to offer smart kitchen solutions that are functional, safe, and made in India. The MLM model helps us reach deeper into Indian households, create job opportunities, and promote self-reliance,' adds Garg. 'This reflects the true spirit of 'Desh ka paisa desh mein'—a movement toward a healthier, more self-reliant India.' As the Make in India initiative gains traction and local supply chains strengthen, the kitchenware and lifestyle category is poised to become a major driver of domestic consumption and empowerment.
